---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-162644"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2025-07-22T23:59:59+00:00"
generated_at: "2026-05-18T04:29:41.891201+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vor Bio appoints Qing Zuraw as CDO, Michel Detheux and Bo Cumbo as directors

## Summary
- Resignation of director Sven (Bill) Ante Lundberg effective July 17, 2025; no disagreement cited.
- Qing Zuraw appointed CDO; over 25 years in autoimmune diseases; previously led telitacicept trials at RemeGen.
- Zuraw's compensation: $565k base salary, 40% target bonus, $200k signing bonus, 4.37M options, 937k RSUs.
- Board expanded to 10; Michel Detheux (CEO iTeos) and Alexander Cumbo (CEO Solid Biosciences) as independent directors.
- New directors receive $40k cash retainer, initial 60k options, annual 30k options per standard policy.

## SEC filing metadata
- accession: 0001193125-25-162644
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2025-07-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312525162644/0001193125-25-162644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312525162644/d24616d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-162644
- JSON: https://secwatch.observer/filing/0001193125-25-162644.json
- Plain text: https://secwatch.observer/filing/0001193125-25-162644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.